News | July 03, 2025
Asahi Kasei Pharma starts Phase III study of promising CIPN prevention therapy
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
The 16,000-square-foot expansion enhances DuPont’s global sterile operations
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
The company offers customized formulations tailored to align with each brand’s identity and consumer needs
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Strategic focus on COCO-model with a nationwide reach of 501 stores
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Subscribe To Our Newsletter & Stay Updated
